Rules/misleading presentation/US-MIS-047

Risk ordering should not falsely suggest a risk applies only to certain populations or conditions

AI-verifiedwarningFDA guidance · non-bindingRaised as a question — a person decides

Rule

The sequencing of risk statements should not suggest that a risk applies only to a particular population or only under a particular condition when the labeling shows it occurs more broadly; FDA considers risk ordering in assessing whether a piece is misleading.

Check

Read risk statements in the order presented and ask whether a reasonable audience member would infer a conditional or population limitation on a risk that the labeling does not actually support.

Escalate when

When the order of risk statements could be read as attaching a population or condition limitation to a risk that the labeling does not limit.

Where this comes from

Section III.A.4, Hierarchy of Risk Information · page 13. The highlighted words are quoted exactly; a script confirms they appear in the source before the rule can be published.

…DA therefore recommends that the most important risk information, including relevant warnings and contraindications, be placed or stated first, especially in print materials. As discussed in Section III.C.1 (below), manufacturers should also note, however, that risk information should not just be presented in one location in a piece, but should, like benefit information, appear as an integral part of the piece. FDA also considers the order in which risk information is presented to determine whether this ordering suggests that certain risks apply only to certain populations or only under certain conditions when this is not the case. > Example 10: A statement in a broadcast ad that “Patients should not drink alcohol when taking > Drug X. Common side effects are drowsiness and nausea” may suggest that these side effects > occur only if alcohol is consumed when taking the drug. Instead, the sponsor should consider > adding intervening information or changing the order of the presentation so that it is clear the side > effects listed are not…

Open the original at page 13 on fda.gov ↗Read our full copy →

Document: FDA guidance: Presenting Risk Information in Prescription Drug and Medical Device Promotion (see document)
Version: as retrieved — the publisher does not version this document; the fingerprint below identifies the exact file
Retrieved: 2026-09-21 from www.fda.gov
Fingerprint: f5654ab082f6cd4408143f16…

FDA guidance describes the agency's current thinking. It is not binding law, and this rule is a recommendation, not an obligation.

Applies when

Naturepromotional

How this rule was checked

Citation proven by script and passed an independent verifier running on a different model. Not yet confirmed by a human.

Drafted
claude-code:sonnet · 2026-09-21
Independent verification — revise
claude-code:opus · 2026-09-21
Reviewer's reasons
- Supported: the quoted sentence is operative text in Section III.A.4 stating that FDA considers whether the ordering of risk information suggests that risks apply only to certain populations or only under certain conditions when that is not the case. Example 10 (the alcohol/drowsiness sequence) illustrates the same point, so the rule is not built on the example alone.
- Overstated in modality. The source describes a factor FDA considers and, in Example 10, says 'the sponsor should consider adding intervening information or changing the order'. The rule states 'The sequencing of risk statements must not create the false impression...', converting a non-binding consideration into a prohibition.
- Atomic: one question about whether the ordering implies a false conditional limitation on a risk.
- 'judgment' is correct: it turns on what a reasonable audience member would infer from the order, which is an impression.
- Authority 'guidance' matches the source document and the rule claims no more than the document's authority. Category, severity 'warning', 'promotional' scope and locator (Section III.A.4, Hierarchy of Risk Information) are all correct; the source expressly says this applies regardless of whether the piece is directed at healthcare professionals or consumers, so no audience limit is missing.
- The quote is a complete sentence with its subject intact.
- Minor: the 'Escalate when' condition is drawn narrowly from Example 10 and is narrower than the check itself, which could cause genuine ordering problems in other shapes to go unescalated.
Revised by the drafter
claude-code:sonnet · 2026-09-21
Revised by the drafter
claude-code:sonnet · 2026-09-21
Independent verification — pass
claude-code:opus · 2026-09-21
Reviewer's reasons
- The quote is a complete sentence stating FDA considers whether risk ordering suggests risks apply only to certain populations or conditions when that is not the case; Example 10 (alcohol / side effects) illustrates the failure the check looks for.
- The rule is phrased as 'should not' and explicitly frames it as an FDA consideration, not an obligation; the source applies ordering considerations to HCP and consumer pieces alike, so the promotional-only scope with no audience limit is right.
- Inference by a reasonable audience member is a judgment; warning severity and locator (III.A.4) are correct.

Nearby rules

US-RISK-029 US-RISK-030